MAY 14, 2015 01:30 PM PDT

Germline Cancer Genetics in 2015

Speakers
  • Director, Center for Cancer Genetics and Prevention, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute
    Biography
      Dr. Garber received her MD and MPH in 1981 from Yale University School of Medicine. She served her internal medicine residency at Brigham and Women's Hospital, followed by fellowships in hematology at BWH, medical oncology at DFCI, and biostatistics at the National Cancer Institute. She joined DFCI as a fellow in 1985, and now works as a medical oncologist and clinical cancer geneticist.
      <br />
      <br />

    Abstract:

    Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibility genes had been predicted by Knudson and Strong in the so-called "two-hit" hypothesis that was developed based on observations that there were families in which cancers clustered and occurred at younger ages, more often bilaterally in paired organs or as multiple primary tumors, and far more frequently than they did otherwise in the general population. In 2015 there have been hundreds of cancer susceptibility genes identified. Most code for proteins that are involved in DNA repair or other regulatory processes rather than structural proteins. In classical cancer genetics, individuals with cancer or with a family history of the disease may seek evaluation for the possible presence of a cancer predisposition syndrome. If the gene for that syndrome is known, blood or saliva from a family member most likely to carry a predisposing mutation is submitted for analysis to one of the commercial labs. The best candidate in the family would have had a tumor that is a component of the syndrome diagnosed at an early age, for example. Molecular analysis of the germline can be focused on candidate genes (e.g. MMR genes for Lynch syndrome, PTEN for Cowden's syndrome) or performed as part of a panel of cancer susceptibility genes by NGS now available from a number of commercial laboratories. However, incidental identification of germline mutations may now occur in the process of molecular analysis of tumors performed in order to identify therapeutic targets, in the course of which a mutation in a gene that can confer hereditary predisposition may be found. Separate testing of germline material would be indicated to determine whether or not the identified mutation was acquired, and therefore somatic, or germline, which could have implications not only for the patient but also for the family. For some types of cancer, the presence of an underlying hereditary predisposition can affect treatment recommendations or surveillance for additional primary cancers in survivors as well as family members (BRCA1/2 mutations in hereditary breast or ovarian cancer, TP53 mutations in Li Fraumeni Syndrome and radiation oncogenesis, With current whole exome and whole genome analyses being offered to adults and in the prenatal setting, incidental identification of germline mutations in cancer predisposition genes as incidental findings have been part of discussions by genetics and ethicists. Mutations identified in dominant cancer susceptibility genes are on the list of those that should be disclosed in the statement by the American College of Medical Genetics, though there remains some controversy around this issue.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources